Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second generation antipsychotics for schizophrenia.

M S Feltus1, D M Gardner

  • 1QEII Health Sciences Centre; Dalhousie University, Halifax, Canada.

The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A scoping review of self-help cognitive behavioural therapy for insomnia.

Sleep medicine reviews·2024
Same author

Concordance with a STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) Criterion in Nova Scotia, Canada: Benzodiazepine and Zoplicone Prescription Claims by Older Adults with Fall-related Hospitalizaions.

Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique·2016
Same author

Consequences of insect herbivory on grape fine root systems with different growth rates.

Plant, cell & environment·2007
Same author

Serotonin syndrome with prolonged dysphagia.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2004
Same author

First episode psychosis: early intervention strategies with second-generation antipsychotic medications.

International journal of clinical practice·2003
Same author

Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report.

Journal of clinical pharmacy and therapeutics·2003
Same journal

A review of substance abuse monitoring in a social services context: a primer for child protection workers.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
Same journal

Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
Same journal

The impact of an ADHD co-morbidity on the diagnosis of FASD.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
Same journal

Profile of the first 1,400 patients receiving diagnostic evaluations for fetal alcohol spectrum disorder at the Washington State Fetal Alcohol Syndrome Diagnostic & Prevention Network.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
Same journal

Managing fetal alcohol spectrum disorder in the public school system: a needs assessment pilot.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
Same journal

Acute intravascular haemolysis associated with intravenous administration of meropenem in a sixty four year old man.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010
See all related articles

Second-generation antipsychotics offer reduced extrapyramidal side effects for schizophrenia management. However, their efficacy for negative symptoms is inconsistent, necessitating careful treatment selection.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Therapeutics

Background:

  • Schizophrenia management has evolved with the introduction of novel antipsychotic medications.
  • Second-generation antipsychotics (SGAs) represent a significant advancement over older treatments.

Purpose of the Study:

  • To review clinically relevant evidence on the use of second-generation antipsychotics in schizophrenia.
  • To compare the efficacy and safety profiles of available and emerging SGAs.

Main Methods:

  • Comprehensive literature searches of MEDLINE and Cochrane Library.
  • Inclusion of clinical trials, guidelines, reviews, and pharmacoeconomic analyses.
  • Review of related commentaries for enhanced depth and perspective.

Related Experiment Videos

Main Results:

  • SGAs, including clozapine, risperidone, olanzapine, and quetiapine, demonstrate a reduced risk of extrapyramidal side effects and tardive dyskinesia compared to conventional agents.
  • The advantage of SGAs in treating negative symptoms of schizophrenia remains inconsistent and may lack clinical significance.
  • Differential risk profiles for side effects among SGAs require clinical awareness.

Conclusions:

  • The expanding array of antipsychotic options presents opportunities for improved schizophrenia symptom management.
  • Selecting the optimal antipsychotic treatment requires a thorough understanding of comparative efficacy and safety data.
  • Practitioners must be knowledgeable about how SGAs compare to each other and to conventional antipsychotics.